Akeso Biopharma raises $250m to accelerate international clinical trials
Akeso Biopharma has successfully raised approximately $250 million through a share placement, drawing significant recognition from international investment firms. The placement saw a majority of ... Read More
Summit Therapeutics set to begin HARMONi trial of Ivonescimab in EGFR-mutant lung cancer
Summit Therapeutics Inc. has announced a significant milestone in its oncology development efforts, completing patient enrollment for the HARMONi Phase III clinical trial. This pivotal ... Read More
China’s NMPA expands AstraZeneca’s Forxiga use as heart failure treatment
China's National Medical Products Administration (NMPA) has approved AstraZeneca's Forxiga (dapagliflozin) for diminishing the risk of cardiovascular fatalities and hospitalizations in adults diagnosed with symptomatic ... Read More
AstraZeneca, Daiichi Sankyo’s Enhertu approved for breast cancer in China
The National Medical Products Administration (NMPA) of China has granted approval to AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for use as a monotherapy in ... Read More
Gufic Biosciences secures NMPA approval to market Prilocaine (API) in China
Gufic Biosciences has received approval from the National Medical Products Administration (NMPA) in China for its product, Prilocaine (API), an amide-type local anesthetic. The approval ... Read More
Innovent Biologics’ olverembatinib gets Chinese breakthrough therapy status in SDH-deficient GIST
Innovent Biologics has been granted breakthrough therapy designation (BTD) for olverembatinib from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). ... Read More
AstraZeneca’s Forxiga wins approval in China for heart failure treatment
AstraZeneca has announced that its drug, Forxiga (dapagliflozin), has received approval from the Chinese National Medical Products Administration (NMPA) to reduce the risk of cardiovascular ... Read More
Amgen secures breakthrough therapy designation for sotorasib in China
Amgen has achieved a major milestone in the global development of its investigational KRAS G12C inhibitor, sotorasib, with the National Medical Products Administration (NMPA) in ... Read More
Antengene gets NMPA nod for eltanexor phase 1/2 clinical trial in myelodysplastic syndrome
Antengene has been given approval from China’s National Medical Products Administration (NMPA) for a phase 1/2 clinical trial of ATG-016 (eltanexor) in myelodysplastic syndrome (MDS). ... Read More